JP2018516851A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516851A5
JP2018516851A5 JP2017550548A JP2017550548A JP2018516851A5 JP 2018516851 A5 JP2018516851 A5 JP 2018516851A5 JP 2017550548 A JP2017550548 A JP 2017550548A JP 2017550548 A JP2017550548 A JP 2017550548A JP 2018516851 A5 JP2018516851 A5 JP 2018516851A5
Authority
JP
Japan
Prior art keywords
compound
antibody
formula
integer
here
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017550548A
Other languages
English (en)
Japanese (ja)
Other versions
JP6948950B2 (ja
JP2018516851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/024343 external-priority patent/WO2016160615A1/en
Publication of JP2018516851A publication Critical patent/JP2018516851A/ja
Publication of JP2018516851A5 publication Critical patent/JP2018516851A5/ja
Priority to JP2021044152A priority Critical patent/JP2021113191A/ja
Application granted granted Critical
Publication of JP6948950B2 publication Critical patent/JP6948950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017550548A 2015-03-27 2016-03-25 メイタンシノイド誘導体、そのコンジュゲート、及び使用方法 Active JP6948950B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021044152A JP2021113191A (ja) 2015-03-27 2021-03-17 メイタンシノイド誘導体、そのコンジュゲート、及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562139044P 2015-03-27 2015-03-27
US62/139,044 2015-03-27
US201562252239P 2015-11-06 2015-11-06
US62/252,239 2015-11-06
PCT/US2016/024343 WO2016160615A1 (en) 2015-03-27 2016-03-25 Maytansinoid derivatives, conjugates thereof, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021044152A Division JP2021113191A (ja) 2015-03-27 2021-03-17 メイタンシノイド誘導体、そのコンジュゲート、及び使用方法

Publications (3)

Publication Number Publication Date
JP2018516851A JP2018516851A (ja) 2018-06-28
JP2018516851A5 true JP2018516851A5 (enExample) 2019-05-23
JP6948950B2 JP6948950B2 (ja) 2021-10-13

Family

ID=55650789

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017550548A Active JP6948950B2 (ja) 2015-03-27 2016-03-25 メイタンシノイド誘導体、そのコンジュゲート、及び使用方法
JP2021044152A Withdrawn JP2021113191A (ja) 2015-03-27 2021-03-17 メイタンシノイド誘導体、そのコンジュゲート、及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021044152A Withdrawn JP2021113191A (ja) 2015-03-27 2021-03-17 メイタンシノイド誘導体、そのコンジュゲート、及び使用方法

Country Status (17)

Country Link
US (4) US20160375147A1 (enExample)
EP (1) EP3273998B1 (enExample)
JP (2) JP6948950B2 (enExample)
KR (2) KR20240142591A (enExample)
CN (2) CN107995912A (enExample)
AU (1) AU2016243527B2 (enExample)
BR (1) BR112017020149A8 (enExample)
CA (1) CA2978340C (enExample)
CL (1) CL2017002422A1 (enExample)
CO (1) CO2017010890A2 (enExample)
EA (1) EA034950B1 (enExample)
IL (1) IL254267B (enExample)
MX (2) MX386328B (enExample)
PH (1) PH12017501780A1 (enExample)
SG (1) SG11201707148PA (enExample)
WO (1) WO2016160615A1 (enExample)
ZA (1) ZA201706040B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233385C1 (en) 2013-03-15 2019-09-19 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
KR20240142591A (ko) * 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
DK3310800T3 (da) 2015-06-19 2022-02-28 Centurion Biopharma Corp Leveringssystem til styret lægemiddelfrigivelse
US11191844B2 (en) 2015-07-06 2021-12-07 Regeneran Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
KR102885186B1 (ko) 2016-01-25 2025-11-17 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
HRP20221202T1 (hr) 2016-09-23 2022-12-09 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antitijela
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
TWI782930B (zh) * 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US10925971B2 (en) 2016-11-29 2021-02-23 Regeneron Pharmaceuticals, Inc. Methods of treating PRLR positive breast cancer
CA3063871A1 (en) 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Cyclodextrin protein drug conjugates
EP3635009B1 (en) 2017-06-07 2026-02-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
JP7426931B2 (ja) 2017-11-07 2024-02-02 レゲネロン ファーマシューティカルス，インコーポレーテッド 抗体薬物コンジュゲートのための親水性リンカー
JP7442821B2 (ja) * 2017-11-30 2024-03-05 センチュリオン バイオファーマ コーポレイション メイタンシノイド系薬物送達システム
IL278244B2 (en) * 2018-04-30 2026-01-01 Regeneron Pharma Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
CN112638426B (zh) * 2018-09-21 2023-06-16 中国人民解放军军事科学院军事医学研究院 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途
SG11202108525VA (en) 2019-02-21 2021-09-29 Regeneron Pharma Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
US11814428B2 (en) * 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof
AU2020381495A1 (en) 2019-11-15 2022-05-19 Seagen Inc. Methods of treating HER2 positive breast cancer with tucatinib in combination with an anti-HER2 antibody-drug conjugate
CN113292574B (zh) * 2020-02-21 2022-05-03 四川大学 一类手性多环的托品烷化合物及其制备方法和用途
MX2022010599A (es) 2020-02-28 2022-09-09 Regeneron Pharma Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos.
US11701427B2 (en) 2020-04-16 2023-07-18 Regeneron Pharmaceuticals, Inc. Diels-alder conjugation methods
NZ797493A (en) 2020-10-22 2024-05-31 Regeneron Pharma Anti-fgfr2 antibodies and methods of use thereof
WO2022103724A1 (en) 2020-11-10 2022-05-19 Regeneron Pharmaceuticals, Inc. Selenium antibody conjugates

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5566585A (en) * 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20070258987A1 (en) 2000-11-28 2007-11-08 Seattle Genetics, Inc. Recombinant Anti-Cd30 Antibodies and Uses Thereof
EP1258255A1 (en) 2001-05-18 2002-11-20 Boehringer Ingelheim International GmbH Conjugates of an antibody to CD44 and a maytansinoid
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20110250133A1 (en) 2003-01-13 2011-10-13 Bracco Imaging S.P.A. Gastrin releasing peptide compounds
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
CA2530172A1 (en) 2003-06-27 2005-02-10 Abgenix, Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
TW200539855A (en) 2004-03-15 2005-12-16 Wyeth Corp Calicheamicin conjugates
WO2006065533A2 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
CA2591148A1 (en) 2004-12-09 2006-06-15 Centocor, Inc. Anti-integrin immunoconjugates, methods and uses
BRPI0612529A2 (pt) 2005-06-20 2010-11-23 Psma Dev Company Llc conjugados de anticorpo-medicamento de psma
NZ563370A (en) 2005-06-20 2010-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
EP1913002B9 (en) 2005-08-09 2012-04-25 Millennium Pharmaceuticals, Inc. Method of acylating maytansinol with chiral amino acids
MX2008008138A (es) 2005-12-22 2008-11-28 Baxter Int Prueba de activacion de monocito mejorada para tener mejor capacidad para detectar contaminantes pirogenicos sin endotoxina en productos medicos.
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
EP2061814B1 (en) 2006-10-27 2012-06-06 Genentech, Inc. Antibodies and immunoconjugates and uses therefor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
WO2008122039A2 (en) 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
JP2010528285A (ja) 2007-05-23 2010-08-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
CN102083461B (zh) 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
ES2536882T3 (es) 2008-07-21 2015-05-29 Polytherics Limited Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EP2464654B1 (en) 2009-08-10 2014-10-08 UCL Business PLC Thiol protecting group
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
KR20120080611A (ko) 2009-10-06 2012-07-17 이뮤노젠 아이엔씨 효능 있는 접합체 및 친수성 링커
US8501692B2 (en) 2009-12-14 2013-08-06 The Regents Of The University Of Michigan Compositions and methods for altering cocaine esterase activity
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2012005982A2 (en) 2010-07-06 2012-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Reporter for rna polymerase ii termination
EP3960865A1 (en) 2010-08-02 2022-03-02 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
EP2611785B1 (de) 2010-09-01 2014-06-04 Bayer Intellectual Property GmbH N-(tetrazol-5-yl)- und n-(triazol-5-yl)arylcarbonsäureamide und ihre verwendung als herbizide
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
CA2816681A1 (en) 2010-11-03 2012-05-10 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
JP6215194B2 (ja) 2011-05-16 2017-10-18 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 生体直交型薬物活性化
EP2714685B1 (en) 2011-05-27 2016-10-19 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
SG10201605041VA (en) * 2011-06-21 2016-08-30 Immunogen Inc Novel maytansinoid derivatives with peptide linker and conjugates thereof
EP2751076B1 (en) 2011-10-14 2018-04-25 MedImmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
MX358757B (es) 2011-10-14 2018-09-03 Seattle Genetics Inc Pirrolobenzodiazepinas y conjugados dirigidos.
US9526798B2 (en) 2011-10-14 2016-12-27 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
BR112014008888A2 (pt) 2011-10-14 2017-04-18 Seattle Genetics Inc pirrolobenzodiazepinas
WO2013068874A1 (en) 2011-11-11 2013-05-16 Pfizer Inc. Antibody-drug conjugates
MX2014006739A (es) 2011-12-05 2015-06-05 Igenica Biotherapeutics Inc Conjugados de anticuerpo-farmaco y compuestos relacionados, composiciones , y metodos.
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
AU2013279099A1 (en) 2012-06-19 2014-12-18 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates
SI2911699T2 (sl) 2012-10-23 2026-01-30 Synaffix B.V. Modificirano protitelo, protitelo-konjugat in proces za njihovo pripravo
NO2789793T3 (enExample) 2012-10-24 2018-01-27
CA2891280C (en) * 2012-11-24 2018-03-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN103254213B (zh) 2012-12-21 2015-02-25 百奥泰生物科技(广州)有限公司 类美登素酯的制备方法及用于所述方法的组合物
CN104688740A (zh) 2012-12-21 2015-06-10 百奥泰生物科技(广州)有限公司 类美登素衍生物及其制备方法和用途
AU2014233385C1 (en) * 2013-03-15 2019-09-19 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
CN103254311B (zh) 2013-05-09 2015-05-13 齐鲁制药有限公司 一种制备抗体-美登素类生物碱药物偶联物的方法
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6824735B2 (ja) 2013-06-06 2021-02-03 ピエール、ファーブル、メディカマン 抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
WO2014197854A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Novel linkers for antibody-drug conjugates and related compounds, compositions, and methods of use
US20140363454A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Antibody-Drug Conjugates, Compositions and Methods of Use
WO2014197866A1 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Modified antibodies and related compounds, compositions, and methods of use
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
KR102252925B1 (ko) * 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
WO2015081281A1 (en) 2013-11-26 2015-06-04 Segway Orthopaedics, Inc. Surgical blade with viewing aperture
CA3178867A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3077402B1 (en) 2013-12-02 2018-09-19 Hong Kong Baptist University Anticancer maytansinoids with two fused macrocyclic rings
HK1231367A1 (zh) 2014-06-02 2017-12-22 Regeneron Pharmaceuticals, Inc. 抗体药物偶联物、试剂和制备方法及其治疗用途
KR20240142591A (ko) * 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
KR102885186B1 (ko) 2016-01-25 2025-11-17 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
WO2018058001A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
US11814428B2 (en) 2019-09-19 2023-11-14 Regeneron Pharmaceuticals, Inc. Anti-PTCRA antibody-drug conjugates and uses thereof

Similar Documents

Publication Publication Date Title
JP2018516851A5 (enExample)
KR102708103B1 (ko) 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
JP6934010B2 (ja) メイタンシノイド誘導体、そのコンジュゲート、及び使用方法
JP6133431B2 (ja) 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
JP6417421B2 (ja) 荷電連結体及び共役体のためのその使用
KR20250004952A (ko) 캄프토테신 접합체
JPWO2019240288A1 (ja) 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
KR20210053871A (ko) 캄프토테신 접합체
JP7573262B2 (ja) 細胞結合分子の共役のための架橋連結体
SG194567A1 (en) Novel binder-drug conjugates (adcs) and their use
JP2020506951A5 (enExample)
RU2014128467A (ru) Новые коньюгаты связывающее соединение-активное соединение (adc) и их применение
TWI654179B (zh) 放射性醫藥複合物
RU2014146951A (ru) Конъюгаты типа лиганд dr5-лекарственное средство
JP2015500287A (ja) 抗体−薬物のコンジュゲート、ならびに関連する化合物、組成物および方法
TWI838358B (zh) 疏水性奧瑞他汀(auristatin)f化合物及其結合物
JP2019194209A (ja) Ｐｓｍａリガンドコンジュゲートによる併用療法
WO2015153857A1 (en) Methods for enhancing the efficacy of a tumor-directed immune response
JPWO2021177438A5 (enExample)
JP2022540395A (ja) 細胞結合性分子－チューブリシン誘導体共役体及びその調製方法
JP2019536780A (ja) Ｍｅｔ抗体薬物複合体
JP7774882B2 (ja) 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
JP2018168068A (ja) 抗ポドプラニン抗体及び抗体薬物複合体
JP2016540826A5 (enExample)
JPWO2020089687A5 (enExample)